Sensei Biotherapeutics (NASDAQ:FTH) Trading Up 10.5% – Here’s Why

Shares of Sensei Biotherapeutics, Inc. (NASDAQ:FTH) rose 10.5% during trading on Friday . The stock traded as high as $31.50 and last traded at $31.55. 263,397 shares were traded during mid-day trading, an increase of 28% from the average daily volume of 205,415 shares. The stock had previously closed at $28.55.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on FTH. Leerink Partners began coverage on Sensei Biotherapeutics in a research report on Monday, April 20th. They set an “outperform” rating and a $50.00 price objective on the stock. Robert W. Baird assumed coverage on Sensei Biotherapeutics in a report on Friday, June 26th. They issued an “outperform” rating and a $57.00 target price for the company. Weiss Ratings initiated coverage on Sensei Biotherapeutics in a research note on Wednesday, June 17th. They set a “sell (d-)” rating for the company. Loop Capital set a $50.00 price objective on Sensei Biotherapeutics in a research note on Thursday, May 28th. Finally, Wall Street Zen upgraded shares of Sensei Biotherapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Sensei Biotherapeutics currently has an average rating of “Moderate Buy” and an average target price of $54.90.

Sensei Biotherapeutics Stock Up 13.3%

The firm has a market capitalization of $835.67 million, a price-to-earnings ratio of -0.23 and a beta of -0.25. The company has a 50-day moving average price of $26.65.

Sensei Biotherapeutics (NASDAQ:FTH) last issued its earnings results on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter. On average, equities analysts forecast that Sensei Biotherapeutics, Inc. will post -13.18 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Anand Kiran Parikh acquired 2,806 shares of Sensei Biotherapeutics stock in a transaction dated Monday, June 22nd. The stock was acquired at an average price of $19.76 per share, for a total transaction of $55,446.56. Following the transaction, the chief executive officer owned 764,234 shares of the company’s stock, valued at $15,101,263.84. This represents a 0.37% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Brian C. Stephenson bought 5,000 shares of the stock in a transaction dated Wednesday, July 1st. The stock was bought at an average price of $23.50 per share, with a total value of $117,500.00. Following the acquisition, the chief financial officer owned 46,688 shares in the company, valued at approximately $1,097,168. This represents a 11.99% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have purchased 49,494 shares of company stock valued at $1,188,822. 7.00% of the stock is owned by corporate insiders.

Institutional Trading of Sensei Biotherapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC lifted its holdings in shares of Sensei Biotherapeutics by 10.6% in the 4th quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock valued at $123,000 after purchasing an additional 1,100 shares during the last quarter. Bank of America Corp DE grew its stake in Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after buying an additional 32,719 shares during the last quarter. Stempoint Capital LP acquired a new position in Sensei Biotherapeutics during the first quarter worth approximately $4,188,000. Finally, Vivo Capital LLC acquired a new position in Sensei Biotherapeutics during the first quarter worth approximately $22,758,000. Institutional investors and hedge funds own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.